ViewRay up as pancreatic cancer trial meets primary goal

Viewray

24/10/2022 12:23

** Shares of ViewRay Inc  VRAY.O  rise 2.3% to ~$4 before
the bell
    ** Co's mid-stage study in treating pancreatic cancer
patients meets primary goal  urn:newsml:reuters.com:*:nPnbGTq3Va
    ** The study tested VRAY's MRIdian radiation therapy system
on 136 patients and observed no incidences of acute
gastrointestinal toxicity (GI)
    ** GI is common side effect of most chemotherapy agents and
account for dose-limiting effects in cancer patients 
    ** The MRIdian radiation therapy system helps in treatment
of cancer by improving targeting precision for higher and
potentially more effective radiation doses against tumors - Co
    ** Up to Friday's close, stock down 28.7% YTD
 (Reporting by Pratik Jain)
 ((Pratik.Jain@thomsonreuters.com;))